SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANDRX-Reaffirm Outperform Recommendation-Gruntal Research
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PAUL ROBERT ST. ONGE who wrote (2)11/7/1996 9:34:00 PM
From: James Silverman   of 23
 
Paul,
Why do you expect an early approval, given Hoechst has filed patent claims against AndRx regarding their Cardizem CD knockoff? This is outstanding litigation and I personally don't believe the AndRx version will be approve as quickly as you think. Additionally, the FDA doesn't exactly fastrack generics.

$80 also sounds a bit aggressive, remember that target comes from the AndRx underwriters.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News